Accepted Manuscript

Hot Topic

Rationale for combination of therapeutic antibodies targeting tumor cells and immune checkpoint receptors: harnessing innate and adaptive immunity through IgG1 isotype immune effector stimulation

Robert L. Ferris, Heinz-Josef Lenz, Anna Maria Trotta, Jesús García-Foncillas, Jeltje Schulten, François Audhuy, Marco Merlano, Gerard Milano

PII: S0305-7372(17)30200-1


DOI: https://doi.org/10.1016/j.ctrv.2017.11.008

Reference: YCTRV 1705

To appear in: Cancer Treatment Reviews Cancer Treatment Re-

views

Received Date: 21 August 2017 Revised Date: 17 November 2017 Accepted Date: 18 November 2017



Please cite this article as: Ferris, R.L., Lenz, H-J., Maria Trotta, A., García-Foncillas, J., Schulten, J., Audhuy, F., Merlano, M., Milano, G., Rationale for combination of therapeutic antibodies targeting tumor cells and immune checkpoint receptors: harnessing innate and adaptive immunity through IgG1 isotype immune effector stimulation, *Cancer Treatment Reviews Cancer Treatment Reviews* (2017), doi: https://doi.org/10.1016/j.ctrv.2017.11.008

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

ACCEPTED MANUSCRIPT

Title: Rationale for combination of therapeutic antibodies targeting tumor cells and immune checkpoint receptors: harnessing innate and adaptive immunity through IgG1 isotype immune effector stimulation

Robert L. Ferris^a, Heinz-Josef Lenz^b, Anna Maria Trotta^c, Jesús García-Foncillas^d, Jeltje Schulten^e, François Audhuy^f, Marco Merlano^g, Gerard Milano^h

^a Department of Otolaryngology, University of Pittsburgh Cancer Institute, University of Pittsburgh, 5117 Centre Avenue, Suite 2.26; Pittsburgh, PA, 15213, United States; ^b Division of Medical Oncology, University of Southern California Norris Cancer Center, Los Angeles, CA, United States; ^c Immunology Unit Functional Genomics, Istituto Nazionale per lo Studio e la Cura dei Tumori "Fondazione Giovanni Pascale," Naples, Italy; ^d Cancer Institute, "Fundación Jiménez Díaz" University Hospital, Autonomous University, Madrid, Spain; ^e Merck KGaA, Darmstadt, Germany; ^f Merck Santé SAS and Merck Serono SAS; 37 rue Saint-Romain 69008, Lyon, France; ^g Department of Medicine, Head Clinical Oncology and Translational Research S. Croce and Carle University Teaching Hospital and ARCO Foundation, via M. Coppino 26, 12100 Cuneo, Italy, mcmerlano@gmail.com; ^h Oncopharmacology Unit, Centre Antoine Lacassagne, 33 avenue Valombrose, 06189 Nice, Cedex 2, France.

Corresponding Authors' Contact Information:

Dr Gerard Milano Centre Antoine Lacassagne 33 avenue Valombrose 06189 Nice Cedex 2 France Phone: (+33) 4 92 03 15 53

Email: gerard.milano@nice.unicancer.fr

Dr. Robert L. Ferris UPMC Hillman Cancer Center 5117 Centre Avenue Suite 2.26 Pittsburgh, PA 15213 Phone:412-623-3959

Email: ferrrl@UPMC.EDU

Download English Version:

https://daneshyari.com/en/article/8785898

Download Persian Version:

https://daneshyari.com/article/8785898

<u>Daneshyari.com</u>